

Pediatric dyslipidemia: Evaluating the use of statins in children.

Helene Digregorio*

Department of Internal Medicine, Houston Methodist Hospital, Houston, Texas

Introduction

Statins, commonly known for their cholesterol-lowering properties, have been widely prescribed to adults for cardiovascular disease prevention. However, their use in pediatric populations has gained attention in recent years due to the increasing prevalence of dyslipidemia among children and adolescents. The rationale for prescribing statins to children primarily revolves around the rising rates of obesity and type 2 diabetes, which are contributing factors to early-onset cardiovascular diseases. The pharmacological action of statins involves inhibiting HMG-CoA reductase, an enzyme crucial for cholesterol synthesis in the liver. By reducing cholesterol production, statins effectively lower low-density lipoprotein (LDL) levels, which are associated with the development of atherosclerosis. While the majority of statin research has focused on adult populations, several studies have explored the safety and efficacy of these medications in younger individuals. The evidence suggests that statins can lead to significant reductions in LDL cholesterol in pediatric patients, particularly in those with familial hypercholesterolemia. [1,2].

However, the prescription of statins in children raises important considerations regarding long-term safety and efficacy. The pediatric population is different from adults in terms of metabolism, growth, and development, which makes it essential to assess the impact of statin therapy on children's overall health. Some studies have reported side effects such as muscle pain, liver enzyme elevation, and gastrointestinal disturbances, though these are generally mild and reversible. Long-term data on the impact of statins on growth and development in children remains limited, necessitating careful monitoring. Another critical aspect of statin therapy in pediatrics is the identification of appropriate candidates for treatment. Guidelines suggest considering statins in children aged 10 years and older who have significantly elevated LDL levels or those with a family history of premature cardiovascular disease. Moreover, lifestyle modifications, including dietary changes and increased physical activity, should be emphasized as the first line of treatment before considering pharmacological interventions. [3,4].

In addition to assessing the clinical effectiveness of statins, it is vital to address the psychological and social implications of prescribing these medications to children. Children with dyslipidemia may experience stigma or anxiety related to their condition, which can affect their adherence to treatment. Healthcare providers must ensure that discussions about statin

therapy are framed positively, emphasizing the benefits of managing cholesterol levels for long-term health. The current landscape of pediatric statin use is evolving, with ongoing research aimed at understanding the long-term outcomes of statin therapy in younger populations. Recent clinical trials and observational studies are shedding light on the benefits and risks associated with early intervention in children with dyslipidemia. The growing body of evidence may lead to revised guidelines that better reflect the need for early treatment and the role of statins in preventing future cardiovascular events in children. [5,6].

As pediatricians and healthcare providers gain more insights into the complexities of treating dyslipidemia in children, there is an increasing emphasis on a multidisciplinary approach. Collaboration among pediatricians, dietitians, exercise physiologists, and mental health professionals is essential for developing comprehensive treatment plans. By addressing not only the medical aspects of statin therapy but also the lifestyle and psychological factors affecting children, healthcare teams can provide holistic care that promotes both physical and emotional well-being. Education plays a pivotal role in the management of pediatric dyslipidemia. Families must be informed about the nature of the condition, the role of cholesterol in cardiovascular health, and the potential benefits and risks of statin therapy. Clear communication can help dispel myths and reduce anxiety associated with medication. Moreover, empowering children and their families to take an active role in their treatment through lifestyle modifications can foster a sense of agency and encourage adherence to recommended interventions. [7,8].

The implementation of regular follow-up appointments is crucial for monitoring the effects of statin therapy in pediatric patients. Routine assessments can help evaluate cholesterol levels, monitor for side effects, and ensure adherence to both medication and lifestyle changes. These visits also provide an opportunity for healthcare providers to reinforce the importance of maintaining a healthy lifestyle and adjusting treatment plans as necessary. Continuous engagement with families can help cultivate a supportive environment that encourages long-term commitment to cardiovascular health. Looking ahead, ongoing research is essential to address the gaps in knowledge regarding the long-term effects of statins in children. Large-scale, multicenter studies that evaluate the safety, efficacy, and impact on growth and development will be invaluable for guiding clinical practice. Furthermore, understanding the

*Correspondence to: Digregorio H *, Department of Internal Medicine, Houston Methodist Hospital, Houston, Texas. Email: hrdigregorio@Houstonmethodist.org

Received: 01-Oct-2024, Manuscript No. AACC-24-150745; Editor assigned: 03-Oct-2024, Pre QC No. AACC-24-150745(PQ); Reviewed: 17-Oct-2024, QC No. AACC-24-150745;

Revised: 24-Oct-2024, Manuscript No. AACC-24-150745(R), Published: 30-Oct-2024, DOI:10.35841/aacc-8.10.335

genetic factors that contribute to dyslipidemia and individual responses to statin therapy may lead to more personalized treatment approaches. The potential for precision medicine in pediatrics is an exciting frontier that could optimize outcomes for children at risk of cardiovascular disease. [9,10].

Conclusion

While statins can be an effective treatment option for managing dyslipidemia in pediatric patients, their use must be approached with caution. A comprehensive assessment of the risks and benefits, combined with a focus on lifestyle modifications, is essential for optimizing cardiovascular health in children. As research continues to advance, healthcare providers will be better equipped to make informed decisions regarding statin therapy, ultimately aiming to reduce the burden of cardiovascular disease in future generations.

References

1. Basso C, Valente M, Poletti A, et al. Surgical pathology of primary cardiac and pericardial tumors. *Eur J Cardiothorac Surg.* 1997;12:730–737.
2. Jain D, Maleszewski JJ, Halushka MK. Benign cardiac tumors and tumor like conditions. *Ann Diagn Pathol.* 2010;14:215–230.
3. Jain S, Maleszewski JJ, Stephenson CR, et al. Current diagnosis and management of cardiac myxomas. *Expert Rev Cardiovasc Ther.* 2015;13:369–375.
4. Maleszewski JJ, Anavekar NS, Moynihan TJ, et al. Pathology, imaging, and treatment of cardiac tumours. *Nat Rev Cardiol.* 2017;14(9):536–549.
5. Oliveira GH, Al-Kindi SG, Hoimes C, et al. Characteristics and survival of malignant cardiac tumors: a 40-year analysis of > 500 patients. *Circulation.* 2015;132:2395–2402.
6. Barron HV, Harr SD, Radford MJ, et al. The association between white blood cell count and acute myocardial infarction mortality in patients > or = 65years of age: findings from the cooperative cardiovascular project. *J Am Coll Cardiol.* 2001;38:1654-1661.
7. Figueroa AL, Takx RA, MacNabb MH, et al. Relationship between measures of adiposity, arterial inflammation, and subsequent cardiovascular events. *Circ Cardiovasc Imaging.* 2016;9:e004043.
8. Frigerio M, Roubina E. Drugs for left ventricular remodeling in heart failure. *Am J Cardiol.* 2005;96:10L-18L.
9. Heo GS, Kopecky B, Sultan D, et al. Molecular imaging visualizes recruitment of inflammatory monocytes and macrophages to the injured heart. *Circ Res.* 2019;124:881-890.
10. Lindner D, Zietsch C, Tank J, Sossalla S, Fluschnik N, Hinrichs S, et al. Cardiac fibroblasts support cardiac inflammation in heart failure. *Basic Res Cardiol.* 2014;109:428.